Religare posts ₹47 Cr consolidated net loss in Q1 FY27 on insurance segment swing

Religare Enterprises' consolidated Q1 FY27 (quarter ended June 30, 2026) results show a swing to a net loss of ₹46.98 Cr, against a profit of ₹95.65 Cr in Q4 FY26 and ₹8.17 Cr in Q1 FY26 — consolidated is the primary basis since the insurance subsidiary dominates group revenue. Consolidated revenue from operations rose 26.4% YoY to ₹2,353.40 Cr, driven mainly by insurance premium income, but fell 4.6% QoQ from ₹2,467.42 Cr. Net margin turned negative at -1.99%, reversing from +3.87% in Q4 FY26 and +0.44% in Q1 FY26. No street consensus estimate could be located for this print, so vsStreet is unknown. The loss is concentrated in the insurance segment (Care Health Insurance), whose segment result swung to a loss of ₹87.27 Cr from a profit of ₹41.26 Cr in Q4 FY26 and a smaller loss of ₹8.30 Cr in Q1 FY26. Two lines drove this: other expenses (largely insurance claims and policy benefits) rose 18.6% QoQ to ₹1,709.97 Cr even as insurance premium income (net) fell to ₹1,978.27 Cr from ₹2,132.37 Cr in Q4 FY26; and the company booked a net loss on fair value changes of ₹71.65 Cr this quarter versus nil in the prior quarter, likely reflecting mark-to-market movement on the insurance investment portfolio. None of these items are labelled exceptional in the filing, so no adjusted-PAT figure is warranted — this reads as an operating and investment-portfolio swing rather than a one-off. Against management's Q4 FY26 guidance — 18-24% GWP growth and a combined ratio near 100% within two years for Care Health Insurance, plus execution of the REL-RFL demerger as the overarching strategic priority — this quarter reads as a miss: the insurance segment posted a loss rather than progress toward the combined-ratio target, and the RBI rejected the REL-RFL demerger scheme via a letter dated August 6, 2026 (Note 9), a setback to the stated strategy of creating two focused listed entities. No press release or management commentary was available to extract for this filing, so there is no management framing to reconcile against the numbers. On a standalone (parent-only) basis, the loss widened YoY to ₹9.62 Cr from ₹6.15 Cr, though it narrowed QoQ from ₹12.36 Cr — broadly consistent with the group figure, which is dominated by the insurance subsidiary. Other Q1 developments include CHIL's allotment of ₹200 Cr subordinated debt, the company's ₹119.69 Cr subscription to CHIL's rights issue, and allotment of 83.43 lakh shares (₹147.05 Cr received) on warrant conversion; SEBI separately disposed a show-cause notice against the company without directions on August 3, 2026.